Literature DB >> 9054374

Mutations in the second cytoplasmic loop of the rat parathyroid hormone (PTH)/PTH-related protein receptor result in selective loss of PTH-stimulated phospholipase C activity.

A Iida-Klein1, J Guo, M Takemura, M T Drake, J T Potts, A Abou-Samra, F R Bringhurst, G V Segre.   

Abstract

To define the structural requirements of the parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor necessary for activation of phospholipase C (PLC), receptors with random mutations in their second cytoplasmic loop were synthesized, and their properties were assessed. A mutant in which the wild type (WT) rat PTH/PTHrP receptor sequence EKKY (amino acids 317-320) was replaced with DSEL had little or no PTH-stimulated PLC activity when expressed transiently in COS-7 cells, but it retained full capacity to bind ligand and to generate cAMP. This phenotype was confirmed in LLC-PK1 cells stably expressing the DSEL mutant receptor, where both PTH-stimulated PLC activity and sodium-dependent phosphate co-transport were essentially abolished. Individual mutations of these four residues point to a critical role for Lys-319 in receptor-G protein coupling. PTH-generated IPs were reduced to 27 +/- 13% when K319E, compared with the WT receptor, and PLC activation was fully recovered in a receptor revertant in which Glu-319 in the DSEL mutant cassette was restored to the WT residue, Lys. Moreover, the WT receptor and a mutant receptor in which K319R had indistinguishable properties, thus suggesting that a basic amino acid at this position may be important for PLC activation. All of these receptors had unimpaired capacity to bind ligand and to generate cAMP. To ensure adequacy of Galphaq-subunits for transducing the receptor signal, Galphaq was expressed in HEK293 and in LLC-PK1 cells together with either WT receptors or receptors with the DSEL mutant cassette. PTH generated no inositol phosphates (IPs) in either HEK293 or LLC-PK1 cells, when they expressed DSEL mutant receptors together with Galphaq. In contrast, PTH generated 2- and 2. 5-fold increases in IPs, respectively, when these cells co-expressed both the WT receptor and Galphaq. Thus, generation of IPs by the activated PTH/PTHrP receptor can be selectively abolished without affecting its capacity to generate cAMP, and Lys-319 in the second intracellular loop is critical for activating the PLC pathway. Moreover, alpha-subunits of the Gq family, rather than betagamma-subunits, transduce the signal from the activated receptor to PLC, and the PLC, rather than the adenylyl cyclase, pathway mediates sodium-dependent phosphate co-transport in LLC-PK1 cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9054374     DOI: 10.1074/jbc.272.11.6882

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

Review 1.  Interaction of PTH and PTHrP with their receptors.

Authors:  T J Gardella; H Jüppner
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

Review 2.  The PTH/PTHrP receptor in Jansen's metaphyseal chondrodysplasia.

Authors:  L M Calvi; E Schipani
Journal:  J Endocrinol Invest       Date:  2000-09       Impact factor: 4.256

3.  Differential determinants for coupling of distinct G proteins with the class B secretin receptor.

Authors:  Gene L Garcia; Maoqing Dong; Laurence J Miller
Journal:  Am J Physiol Cell Physiol       Date:  2012-01-25       Impact factor: 4.249

4.  Phospholipase C signaling via the parathyroid hormone (PTH)/PTH-related peptide receptor is essential for normal bone responses to PTH.

Authors:  Jun Guo; Minlin Liu; Dehong Yang; Mary L Bouxsein; Clare C Thomas; Ernestina Schipani; F Richard Bringhurst; Henry M Kronenberg
Journal:  Endocrinology       Date:  2010-05-25       Impact factor: 4.736

5.  Renal phosphate wasting in the absence of adenylyl cyclase 6.

Authors:  Robert A Fenton; Fiona Murray; Jessica A Dominguez Rieg; Tong Tang; Moshe Levi; Timo Rieg
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

6.  Characterization of a PTH1R missense mutation responsible for Jansen type metaphyseal chondrodysplasia.

Authors:  Junko Shimomura-Kuroki; Muhammad Farooq; Tsuneo Sekimoto; Norio Amizuka; Yutaka Shimomura
Journal:  Odontology       Date:  2016-05-09       Impact factor: 2.634

Review 7.  Heterotrimeric G proteins in the control of parathyroid hormone actions.

Authors:  Murat Bastepe; Serap Turan; Qing He
Journal:  J Mol Endocrinol       Date:  2017-05       Impact factor: 5.098

Review 8.  The bone-building action of the parathyroid hormone: implications for the treatment of osteoporosis.

Authors:  J F Whitfield; P Morley; G E Willick
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

9.  Mechanisms of ligand binding to the parathyroid hormone (PTH)/PTH-related protein receptor: selectivity of a modified PTH(1-15) radioligand for GalphaS-coupled receptor conformations.

Authors:  Thomas Dean; Agnes Linglart; Matthew J Mahon; Murat Bastepe; Harald Jüppner; John T Potts; Thomas J Gardella
Journal:  Mol Endocrinol       Date:  2005-12-08

10.  Eliminating phosphorylation sites of the parathyroid hormone receptor type 1 differentially affects stimulation of phospholipase C and receptor internalization.

Authors:  Susanne U Miedlich; Abdul B Abou-Samra
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-06-24       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.